Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Merck | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Merck

KEYTRUDA drives growth in the quarter, up 166% to $1.3 billion

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Merck
4Q Revenues: $10.4 billion (+3%)
4Q Loss: $872 million (loss of $594 million 4Q16)  
FY Revenues:$40.1 billion (+1%)
FY Earnings: $2.6 billion (-34%)
Comments: Pharmaceutical sales increased 4% to $9.3 billion in the quarter, driven primarily by significant growth of KEYTRUDA, up 166% to $1.3 billion, reflecting continued launches with new indications globally. Sales of GARDASIL were $633 million, up 17% in the quarter and include approximately $115 million for the partial replenishment of doses of GARDASIL 9 that were borrowed from the U.S. CDC Pediatric Vaccine Stockpile in the third quarter. Januvia sales were $1.5 billion, up 1%. Zetia/Vytorin sales were down 42% to $509 million in the quarter due to loss of U.S. market exclusivity. Sales of PROQUAD, M-M-R II and VARIVAX were flat at $403 million. ISENTRESS sales were $308 million, down 9% in the quarter. ZEPATIER sales were up 29% to $296 million, due to ongoing launches across Europe and Asia Pacific. Revenue in the fourth quarter and full year of 2017 was unfavorably affected by approximately $125 million and $260 million, respectively, from lost sales in certain markets related to the cyber-attack that occurred in June.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters